Caffeine metabolism in premature infants

被引:28
作者
Al-Alaiyan, S
Al-Rawithi, S
Raines, D
Yusuf, A
Legayada, E
Shoukri, MM
El-Yazigi, A
机构
[1] King Faisal Specialist Hosp & Res Ctr, Dept Pediat, Sect Neonatol, Riyadh 11211, Saudi Arabia
[2] King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res, Pharmacokinet Lab, Riyadh 11211, Saudi Arabia
[3] King Faisal Specialist Hosp & Res Ctr, Biostat Epidemiol & Sci Comp Dept, Riyadh 11211, Saudi Arabia
关键词
D O I
10.1177/00912700122010500
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Caffeine has been used frequently in the treatment and prevention of apnea of prematurity. The metabolism of caffeine depends on the activities of the hepatic enzymes that vary from one infant to another. The objective of this study was to determine the influence of postnatal age (PNA), birth weight (BW) study weight (SW), gestational age (GA), postconceptual age (PCA), and gender on the maturation of caffeine metabolism in premature infants. The caffeine base was administered orally as a loading dose of 10 mg/kg, followed by a maintenance dose of 2 mg/kg every 24 hours. The steady-state concentration of caffeine and metabolites was measured in plasma taken on the 5th-day postloading dose. The molar concentration ratios for the N3 (N3-), N7 (N7-), N1 (N1-), and all methyl (Nall-) demethylation processes; clearance (CL); and the percentage of molar concentration of caffeine found in plasma to that of the total caffeine and metabolites (%CAF) were calculated from samples collected from 80 neonatal infants. The 48 male and 32 female premature infants had median (range) BW (g) GA (weeks), SW (g), PCA (weeks) and PNA (days) of 1300 (650-2260), 30 (24-34), 1630 (980-2670), 34 (29-40), and 28 (5-60), respectively The median (range) of the ratios for the %CAF, CL, and the N3-, N7-, N1-, and Nall- were 86.9 (52.9-99.0), 0.127 (0.046-0.503) ml . kg(-1). min(-1), 0.032 (0-0.438), 0.070 (0.007-0.471), 0.026 (0-0.28), and 0.0463 (0.003-0.303), respectively. When the patients were stratified into four PNA age groups, each older group showed a consistently higher level of caffeine metabolic activity for the N3-, N7-, and N1-pathways with a corresponding decrease in the %CAF whereas no significant differences were seen for the N1 - pathway or for CL. No pattern of significant differences between the demethylation process ratios, %CAF: or CL was seen between groups of infants when th ey were stratified according to BW, SW PCA, or GA. The female infants were found to have significantly higher rates of caffeine metabolism as shown by %CAF: N1-, N3-, and Nall- processes but not the N7-. Multivariate linear regression analysis by two methods demonstrated that PNA is significantly related to % CAF and Nall-, whereas the female patients had higher levels of metabolic activity for the %CAF and N1- process. The authors conclude that the N7-demethy-lation process is the predominate caffeine metabolic process in premature infants. Furthermore, the maturation of the caffeine metabolism in premature infants with a PNA of less than 60 days increases with postnatal age, regardless of birth weight, gestational age, postconceptual age, and study weight. The female neonatal patients demonstrated a higher rate of caffeine metabolism than the males.
引用
收藏
页码:620 / 627
页数:8
相关论文
共 27 条
[1]   MATURATION OF CAFFEINE ELIMINATION IN INFANCY [J].
ARANDA, JV ;
COLLINGE, JM ;
ZINMAN, R ;
WATTERS, G .
ARCHIVES OF DISEASE IN CHILDHOOD, 1979, 54 (12) :946-949
[2]   EFFICACY OF CAFFEINE IN TREATMENT OF APNEA IN LOW-BIRTH-WEIGHT INFANT [J].
ARANDA, JV ;
GORMAN, W ;
BERGSTEINSSON, H ;
GUNN, T .
JOURNAL OF PEDIATRICS, 1977, 90 (03) :467-472
[3]  
ARNAUD MJ, 1984, CAFFEINE PERSPECTIVE, P3
[4]   CAFFEINE AND THEOPHYLLINE METABOLISM IN NEWBORN AND ADULT HUMAN HEPATOCYTES - COMPARISON WITH ADULT-RAT HEPATOCYTES [J].
BERTHOU, F ;
RATANASAVANH, D ;
ALIX, D ;
CARLHANT, D ;
RICHE, C ;
GUILLOUZO, A .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (19) :3691-3700
[5]   USE OF SALIVARY LEVELS TO PREDICT CLEARANCE OF CAFFEINE IN PATIENTS WITH CYSTIC-FIBROSIS [J].
BIANCHETTI, MG ;
KRAEMER, R ;
PASSWEG, J ;
JOST, J ;
PREISIG, R .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1988, 7 (05) :688-693
[6]   MATURATION OF CAFFEINE METABOLIC PATHWAYS IN INFANCY [J].
CARRIER, O ;
PONS, G ;
REY, E ;
RICHARD, MO ;
MORAN, C ;
BADOUAL, J ;
OLIVE, G .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (02) :145-151
[7]   Salivary clearance and urinary metabolic pattern of caffeine in healthy children and in pediatric patients with hepatocellular diseases [J].
El-Yazigi, A ;
Shabib, S ;
Al-Rawithi, S ;
Yusuf, A ;
Legayada, ES ;
Al-Humidan, A .
JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (04) :366-372
[8]  
ELYAZIGI A, 1989, CLIN CHEM, V35, P848
[9]   Evaluation of caffeine as a test drug for CYPIA2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations [J].
Fuhr, U ;
Rost, KL ;
Engelhardt, R ;
Sachs, M ;
Liermann, D ;
Belloc, C ;
Beaune, P ;
Janezic, S ;
Grant, D ;
Meyer, UA ;
Staib, AH .
PHARMACOGENETICS, 1996, 6 (02) :159-176
[10]   PHARMACOKINETIC ASPECTS OF CAFFEINE IN PREMATURE-INFANTS WITH APNEA [J].
GORODISCHER, R ;
KARPLUS, M .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 22 (01) :47-52